Hemostemix (CVE:HEM) Trading 38.1% Higher – Still a Buy?

by · The Cerbat Gem

Hemostemix Inc. (CVE:HEMGet Free Report)’s stock price traded up 38.1% during mid-day trading on Wednesday . The stock traded as high as C$0.15 and last traded at C$0.15. 605,625 shares were traded during mid-day trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.

Hemostemix Price Performance

The firm has a market capitalization of C$12.63 million, a price-to-earnings ratio of -7.25 and a beta of 0.20. The business’s 50-day moving average price is C$0.09 and its 200 day moving average price is C$0.07.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Recommended Stories